CAS 1410880-22-6

Benzamide, 3-[[4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-

CAS : 1410880-22-6

Formule : C₂₉H₂₉N₇O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 507.5863

Ref: IN-DA001FVN

JNK-IN-8

CAS : 1410880-22-6

JNK-IN-8

Formule : C₂₉H₂₉N₇O₂

Degré de pureté : ≥98%

Masse moléculaire : 507.59

Ref: 54-BUP10090

JNK-IN-8

CAS : 1410880-22-6

3-(4-(Dimethylamino)but-2-enamido)-N-(3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide

Formule : C₂₉H₂₉N₇O₂

Degré de pureté : 98%

Masse moléculaire : 507.59

Ref: IN-DG630240

JNK-IN-8

CAS : 1410880-22-6

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM).

Formule : C₂₉H₂₉N₇O₂

Degré de pureté : 98.28% - >99.99%

Couleur et forme : White Solid

Masse moléculaire : 507.59

Ref: TM-T2668

JNK-IN-8

CAS : 1410880-22-6

Degré de pureté : 98%

Masse moléculaire : 507.238

Ref: 10-F980080

JNK Inhibitor XVI

CAS : 1410880-22-6

JNK inhibitor XVI is an inhibitor drug that inhibits the JNK protein kinase, which is a member of the MAPK family. It has been shown to inhibit the growth of breast cancer cells in vitro. JNK inhibitor XVI also inhibits autophagy and reactive oxygen species production in these cells, leading to cell death. This drug may be a potential treatment for colorectal adenocarcinoma and epidermal growth factor receptor (EGFR) -positive cancer.

Formule : C₂₉H₂₉N₇O₂

Degré de pureté : Min. 95%

Masse moléculaire : 507.59 g/mol

Ref: 3D-KGC88022